Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-100 Open Label Extension in Duchenne Muscular Dystrophy
NCT01978366Phase 2Terminated
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Oct 2013
- Primary completion
- Apr 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of halofuginone in Duchenne muscular dystrophy (DMD), sponsored by Processa Pharmaceuticals, Inc.. Started Oct 2013; status: terminated.
02
Drugs
halofuginone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01978366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01978366.